Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BioNTech
Biotech
BioNTech’s B7-H3 ADC hits ph. 3 at half the size of Merck’s
BioNTech's DualityBio-partnered BNT324 achieved a median rPFS length of 11.3 months in heavily pretreated patients with mCRPC.
Angus Liu
Feb 27, 2026 10:31pm
Biotech money moves: 3 new venture funds raise nearly $1B
Jan 9, 2026 1:20pm
BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial
Dec 8, 2025 7:47am
Pfizer lays out its PD-1xVEGF bispecific research strategy
Nov 11, 2025 11:43am
Pfizer pulls the plug on 11 programs
Nov 4, 2025 2:40pm
BioNTech fades cancer vax in late-stage melanoma setting
Oct 20, 2025 3:01pm